Vaginal innate immunity: alteration during pregnancy and its impact on pregnancy outcomes

References

• Donders G, De Wet HG, Hooft P, Desmyter J. Lactobacilli in Papanicolaou smears, genital infections, and pregnancy. Am. J. Perinatol.10(5), 358–361 (1993).
   PubMed Web of Science ®Google Scholar
• Donders GG. Bacterial vaginosis during pregnancy: screen and treat? Eur. J. Obstet. Gynecol. Reprod. Biol.83(1), 1–4 (1999).
   Google Scholar
• Leitich H, Brunbauer M, Bodner-Adler B, Kaider A, Egarter C, Husslein P. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol.188(3), 752–758 (2003).
   PubMed Web of Science ®Google Scholar
• Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS22(12), 1493–1501 (2008).
   PubMed Web of Science ®Google Scholar
• Carey JC, Klebanoff MA. Is a change in the vaginal flora associated with an increased risk of preterm birth? Am. J. Obstet. Gynecol.192(4), 1341–1346; discussion 1346–1347 (2005).
   PubMed Web of Science ®Google Scholar
• Boris S, Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infec.2(5), 543–546 (2000).
   PubMed Web of Science ®Google Scholar
• Pybus V, Onderdonk AB. Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis. Microbes Infec.1(4), 285–292 (1999).
   PubMed Web of Science ®Google Scholar
• Taha TE, Hoover DR, Dallabetta GA et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS12(13), 1699–1706 (1998).
   PubMed Web of Science ®Google Scholar
• Martin HL, Richardson BA, Nyange PM et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis.180(6), 1863–1868 (1999).
   PubMed Web of Science ®Google Scholar
• Hill JA, Anderson DJ. Human vaginal leukocytes and the effects of vaginal fluid on lymphocyte and macrophage defense functions. Am. J. Obstet. Gynecol.166(2), 720–726 (1992).
   Google Scholar
• Donders GG, Bosmans E, Dekeersmaecker A, Vereecken A, Van Bulck B, Spitz B. Pathogenesis of abnormal vaginal bacterial flora. Am. J. Obstet. Gynecol.182(4), 872–878 (2000).
   PubMed Web of Science ®Google Scholar
• Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N. Engl. J. Med.353(18), 1899–1911 (2005).
   PubMed Web of Science ®Google Scholar
• Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG109(1), 34–43 (2002).
   PubMed Web of Science ®Google Scholar
• Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin. Diagn. Lab. Immunol.9(1), 92–96 (2002).
   PubMedGoogle Scholar
• Shalev E, Battino S, Weiner E, Colodner R, Keness Y. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch. Fam. Med.5(10), 593–596 (1996).
   PubMedGoogle Scholar
• Stapleton AE, Au-Yeung M, Hooton TM et al. Randomized, placebo-controlled Phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis.52(10), 1212–1217 (2011).
   PubMed Web of Science ®Google Scholar
• Wira CR, Fahey JV. The innate immune system: gatekeeper to the female reproductive tract. Immunology111(1), 13–15 (2004).
   PubMedGoogle Scholar
• Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am. J. Reprod. Immunol.59(1), 27–34 (2008).
   PubMed Web of Science ®Google Scholar
• Ganz T, Selsted ME, Szklarek D et al. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest.76(4), 1427–1435 (1985).
   PubMed Web of Science ®Google Scholar
• Chang TL, Vargas J Jr, DelPortillo A, Klotman ME. Dual role of α-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest.115(3), 765–773 (2005).
   PubMed Web of Science ®Google Scholar
• Quinones-Mateu ME, Lederman MM et al. Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication. AIDS17(16), F39–F48 (2003).
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Caputo SL, Maffeis G et al. Human α defensin in HIV-exposed but uninfected individuals. J. Acquir. Immune Defic. Syndr.35(5), 455–463 (2004).
   Google Scholar
• McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest.96(1), 456–464 (1995).
   PubMed Web of Science ®Google Scholar
• Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin. Diagn. Lab. Immunol.7(3), 515–518 (2000).
   Google Scholar
• Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis.183(4), 653–656 (2001).
   PubMed Web of Science ®Google Scholar
• Novak RM, Donoval BA, Graham PJ et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin. Vaccine Immunol.14(9), 1102–1107 (2007).
   Google Scholar
• Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am. J. Obstet. Gynecol.183(5), 1243–1248 (2000).
   Google Scholar
• Moriyama A, Shimoya K, Ogata I et al. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol. Hum. Reprod.5(7), 656–661 (1999).
   Google Scholar
• Shimoya K, Zhang Q, Temma K et al. Secretory leukocyte protease inhibitor levels in cervicovaginal secretion of elderly women. Maturitas54(2), 141–148 (2006).
   Google Scholar
• King AE, Kelly RW, Sallenave JM, Bocking AD, Challis JRG. Innate immune defences in the human uterus during pregnancy. Placenta28(11–12), 1099–1106 (2007).
   PubMed Web of Science ®Google Scholar
• Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, Zani ML. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie90(2), 284–295 (2008).
   Web of Science ®Google Scholar
• Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR. Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology129(2), 207–219 (2010).
   Google Scholar
• Iqbal SM, Ball TB, Levinson P et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS23(13), 1669–1677 (2009).
   PubMed Web of Science ®Google Scholar
• Stock SJ, Duthie L, Tremaine T, Calder AA, Kelly RW, Riley SC. Elafin (SKALP/Trappin-2/proteinase inhibitor-3) is produced by the cervix in pregnancy and cervicovaginal levels are diminished in bacterial vaginosis. Reprod. Sci.16(12), 1125–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Striz I, Trebichavsky I. Calprotectin – a pleiotropic molecule in acute and chronic inflammation. Physiol. Res.53(3), 245–253 (2004).
   PubMed Web of Science ®Google Scholar
• Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A. The role of calprotectin in obstetrics and gynecology. Eur. J. Obstet. Gynecol. Reprod. Biol.151(1), 3–9 (2010).
   PubMed Web of Science ®Google Scholar
• Kunimi K, Maegawa M, Kamada M et al. Myeloid-related protein-8/14 is associated with proinflammatory cytokines in cervical mucus. J. Reprod. Immunol.71(1), 3–11 (2006).
   PubMed Web of Science ®Google Scholar
• Yano J, Lilly E, Barousse M, Fidel PL Jr. Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect. Immun.78(12), 5126–5137 (2010).
   PubMed Web of Science ®Google Scholar
• Harmsen MC, Swart PJ, de Bethune MP et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis.172(2), 380–388 (1995).
   PubMed Web of Science ®Google Scholar
• Lee-Huang S, Huang PL, Sun Y, Kung HF, Blithe DL, Chen HC. Lysozyme and RNases as anti-HIV components in β-core preparations of human chorionic gonadotropin. Proc. Natl Acad. Sci. USA96(6), 2678–2681 (1999).
   PubMed Web of Science ®Google Scholar
• Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of Rhesus macaques. Lab. Invest.67(5), 628–634 (1992).
   PubMed Web of Science ®Google Scholar
• Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod.73(6), 1253–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Wira CR, Rossoll RM. Antigen-presenting cells in the female reproductive tract: influence of the estrous cycle on antigen presentation by uterine epithelial and stromal cells. Endocrinology136(10), 4526–4534 (1995).
   PubMed Web of Science ®Google Scholar
• Wira CR, Roche MA, Rossoll RM. Antigen presentation by vaginal cells: role of TGFβ as a mediator of estradiol inhibition of antigen presentation. Endocrinology143(8), 2872–2879 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy SP, Hanna NN, Fast LD et al. Evidence for participation of uterine natural killer cells in the mechanisms responsible for spontaneous preterm labor and delivery. Am. J. Obstet. Gynecol.200(3), 308.e1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Gardner L, Moffett A. Dendritic cells in the human decidua. Biol. Reprod.69(4), 1438–1446 (2003).
   PubMed Web of Science ®Google Scholar
• Hachisuga T, Fukuda K, Nakamura S, Iwasaka T, Sugimori H. Local immune response in endometrial carcinomas. Br. J. Obstet. Gynaecol.104(1), 110–114 (1997).
   Google Scholar
• Ma C, Zhang WY, Wang JD. [Expressions of Th, DC, NK cells in cervical tissue and the relationship with immune functions]. Zhonghua Yi Xue Za Zhi89(23), 1650–1653 (2009).
   Google Scholar
• Li XF, Charnock-Jones DS, Zhang E et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J. Clin. Endocrinol. Metab.86(4), 1823–1834 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: maternal care before birth? Cell. Mol. Immunol.8(1), 1–11 (2011).
   Google Scholar
• Darville T, O’Neill JM, Andrews CW Jr, Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol.171(11), 6187–6197 (2003).
   PubMedGoogle Scholar
• Abrahams VM, Visintin I, Aldo PB, Guller S, Romero R, Mor G. A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells. J. Immunol.175(12), 8096–8104 (2005).
   PubMed Web of Science ®Google Scholar
• Holmlund U, Cebers G, Dahlfors AR et al. Expression and regulation of the pattern recognition receptors Toll-like receptor-2 and Toll-like receptor-4 in the human placenta. Immunology107(1), 145–151 (2002).
   PubMed Web of Science ®Google Scholar
• Bulut Y, Faure E, Thomas L et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J. Immunol.168(3), 1435–1440 (2002).
   PubMed Web of Science ®Google Scholar
• O’Connell CM, Ionova IA, Quayle AJ, Visintin A, Ingalls RR. Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen. J. Biol. Chem.281(3), 1652–1659 (2006).
   Google Scholar
• Ilievski V, Lu SJ, Hirsch E. Activation of TLRs 2 or 3 and preterm delivery in the mouse. Reprod. Sci.14(4), 315–320 (2007).
   PubMed Web of Science ®Google Scholar
• Lorenz E, Hallman M, Marttila R, Haataja R, Schwartz DA. Association between the Asp299Gly polymorphisms in the Toll-like receptor 4 and premature births in the Finnish population Pediatr. Res.52(3), 373–376 (2002).
   PubMed Web of Science ®Google Scholar
• Kumazaki K, Nakayama M, Yanagihara I, Suehara N, Wada Y. Immunohistochemical distribution of Toll-like receptor 4 in term and preterm human placentas from normal and complicated pregnancy including chorioamnionitis. Hum. Pathol.35(1), 47–54 (2004).
   PubMed Web of Science ®Google Scholar
• Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin and interleukin-1 α in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. Am. J. Obstet. Gynecol.169(5), 1161–1166 (1993).
   PubMed Web of Science ®Google Scholar
• Sturm-Ramirez K, Gaye-Diallo A, Eisen G, Mboup S, Kanki PJ. High levels of tumor necrosis factor-α and interleukin-1β in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J. Infect. Dis.182(2), 467–473 (2000).
   PubMed Web of Science ®Google Scholar
• Imseis HM, Greig PC, Livengood CH 3rd, Shunior E, Durda P, Erikson M. Characterization of the inflammatory cytokines in the vagina during pregnancy and labor and with bacterial vaginosis. J. Soc. Gynecol. Investig.4(2), 90–94 (1997).
   PubMedGoogle Scholar
• Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet. Gynecol.102(3), 527–534 (2003).
   PubMedGoogle Scholar
• Hedges SR, Sibley DA, Mayo MS, Hook EW 3rd, Russell MW. Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. J. Infect. Dis.178(3), 742–751 (1998).
   PubMed Web of Science ®Google Scholar
• Dybul M, Connors M, Fauci AS. Immunology of HIV Infection. In: Fundamental Immunology. Paul WE (Ed.). Lippincott Williams & Wilkins, PA, USA, 11285–11318 (2003).
   Google Scholar
• Poli G, Kinter AL, Vicenzi E, Fauci AS. Cytokine regulation of acute and chronic HIV infection in vitro: from cell lines to primary mononuclear cells. Res. Immunol.145(8–9), 578–582 (1994).
   Google Scholar
• Shehzad M. Iqbal RK. Mucosal innate immunity as a determinant of HIV Susceptibility. Am. J.Reprod. Immunology59(1), 44–54 (2008).
   Google Scholar
• Giudice LC. Potential biochemical markers of uterine receptivity. Hum. Reprod.14(Suppl. 2), 3–16 (1999).
   PubMed Web of Science ®Google Scholar
• Aghajanova L, Stavreus-Evers A, Nikas Y, Hovatta O, Landgren BM. Coexpression of pinopodes and leukemia inhibitory factor, as well as its receptor, in human endometrium. Fertil. Steril.79(Suppl. 1), 808–814 (2003).
   PubMed Web of Science ®Google Scholar
• Tjernlund A, Walther-Jallow L, Behbahani H et al. Leukemia inhibitor factor (LIF) inhibits HIV-1 replication via restriction of stat 3 activation. AIDS Res. Hum. Retroviruses23(3), 398–406 (2007).
   Google Scholar
• Aboul Enien WM, El Metwally HA. Association of abnormal vaginal flora with increased cervical tumour necrosis factor-α and interferon-γ levels in idiopathic infertility. J. Immunol.12(2), 53–59 (2005).
   Google Scholar
• Conrady CD, Halford WP, Carr DJ. Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J. Virol.85(4), 1625–1633 (2011).
   Google Scholar
• Lu H, Xing Z, Brunham RC. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J. Immunol.169(11), 6324–6331 (2002).
   PubMed Web of Science ®Google Scholar
• Rasmussen SJ, Eckmann L, Quayle AJ et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Invest.99(1), 77–87 (1997).
   PubMed Web of Science ®Google Scholar
• Pellis V, De Seta F, Crovella S et al. Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin. Exp. Immunol.139(1), 120–126 (2005).
   PubMed Web of Science ®Google Scholar
• Wojitani MD, de Aguiar LM, Baracat EC, Linhares IM. Association between mannose-binding lectin and interleukin-1 receptor antagonist gene polymorphisms and recurrent vulvovaginal candidiasis. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-011-1920-z (2011) (Epub ahead of print).
   Google Scholar
• Than NG, Romero R, Erez O et al. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am. J. Reprod Immunol.60(4), 333–345 (2008).
   PubMed Web of Science ®Google Scholar
• Goplerud CP, Ohm MJ, Galask RP. Aerobic and anaerobic flora of the cervix during pregnancy and the puerperium. Am. J. Obstet. Gynecol.126(7), 858–868 (1976).
   PubMed Web of Science ®Google Scholar
• Koumans EH, Sternberg M, Bruce C et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex. Transm. Dis.34(11), 864–869 (2007).
   PubMed Web of Science ®Google Scholar
• Beigi RH, Yudin MH, Cosentino L, Meyn LA, Hillier SL. Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J. Infect. Dis.196(9), 1355–1360 (2007).
   Google Scholar
• Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N. Engl. J. Med.342(20), 1500–1507 (2000).
   PubMed Web of Science ®Google Scholar
• Helmig BR, Romero R, Espinoza J et al. Neutrophil elastase and secretory leukocyte protease inhibitor in prelabor rupture of membranes, parturition and intra-amniotic infection. J. Matern. Fetal Neonatal Med.12(4), 237–246 (2002).
   PubMedGoogle Scholar
• Kutteh WH, Franklin RD. Quantification of immunoglobulins and cytokines in human cervical mucus during each trimester of pregnancy. Am. J. Obstet. Gynecol.184(5), 865–874 (2001).
   Web of Science ®Google Scholar
• Shimaoka Y, Hidaka Y, Tada H et al. Changes in cytokine production during and after normal pregnancy. Am. J. Reprod. Immunol.44(3), 143–147 (2000).
   Google Scholar
• Donders GG, Vereecken A, Bosmans E, Spitz B. Vaginal cytokines in normal pregnancy. Am. J. Obstet. Gynecol.189(5), 1433–1438 (2003).
   PubMed Web of Science ®Google Scholar
• Lee CL, Chiu PC, Lam KK et al. Differential actions of glycodelin-A on Th-1 and Th-2 cells: a paracrine mechanism that could produce the Th-2 dominant environment during pregnancy. Hum. Reprod.26(3), 517–526 (2011).
   Google Scholar
• Doria A, Iaccarino L, Arienti S et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod. Toxicol.22(2), 234–241 (2006).
   PubMed Web of Science ®Google Scholar
• Helmig R, Uldbjerg N, Ohlsson K. Secretory leukocyte protease inhibitor in the cervical mucus and in the fetal membranes. Eur. J. Obstets. Gynecol. Reprod. Biol.59(1), 95–101 (1995).
   Google Scholar
• Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am. J. Obstet. Gynecol.183, 1243–1248 (2000).
   Google Scholar
• Vogel I, Thorsen P, Curry A, Sandager P, Uldbjerg N. Biomarkers for the prediction of preterm delivery. Acta. Obstet. Gynecol. Scand.84(6), 516–525 (2005).
   PubMed Web of Science ®Google Scholar
• Rizzo G, Capponi A, Vlachopoulou A, Angelini E, Grassi C, Romanini C. Ultrasonographic assessment of the uterine cervix and interleukin-8 concentrations in cervical secretions predict intrauterine infection in patients with preterm labor and intact membranes. Ultrasound Obstet. Gynecol.12(2), 86–92 (1998).
   PubMed Web of Science ®Google Scholar
• Simhan HN, Krohn MA. First-trimester cervical inflammatory milieu and subsequent early preterm birth. Am. J. Obstet. Gynecol.200(4), 377.e371–e374 (2009).
   Google Scholar
• Balu RB, Savitz DA, Ananth CV et al. Bacterial vaginosis, vaginal fluid neutrophil defensins, and preterm birth. Obstet. Gynecol.101(5 Pt 1), 862–868 (2003).
   PubMedGoogle Scholar
• Buhimschi IA, Jabr M, Buhimschi CS, Petkova AP, Weiner CP, Saed GM. The novel antimicrobial peptide β3-defensin is produced by the amnion: a possible role of the fetal membranes in innate immunity of the amniotic cavity. Am. J. Obstet. Gynecol.191(5), 1678–1687 (2004).
   PubMed Web of Science ®Google Scholar
• Tromp G, Kuivaniemi H, Romero R et al. Genome-wide expression profiling of fetal membranes reveals a deficient expression of proteinase inhibitor 3 in premature rupture of membranes. Am. J. Obstet. Gynecol.191(4), 1331–1338 (2004).
   PubMed Web of Science ®Google Scholar
• Simhan HN, Caritis SN, Krohn MA, Hillier SL. Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. Am. J. Obstet. Gynecol.189(4), 1150–1154 (2003).
   PubMed Web of Science ®Google Scholar
• Ramsey PS, Lyon MD, Goepfert AR et al. Use of vaginal polymorphonuclear to epithelial cell ratios for the prediction of preterm birth. Obstet. Gynecol.105(1), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobsson B, Holst RM, Wennerholm UB, Andersson B, Lilja H, Hagberg H. Monocyte chemotactic protein-1 in cervical and amniotic fluid: relationship to microbial invasion of the amniotic cavity, intra-amniotic inflammation, and preterm delivery. Am. J. Obstet. Gynecol.189(4), 1161–1167 (2003).
   PubMed Web of Science ®Google Scholar
• Shennan A, Crawshaw S, Briley A et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG113(1), 65–74 (2006).
   PubMed Web of Science ®Google Scholar
• Carey JC, Klebanoff MA, Hauth JC et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. N. Engl. J. Med.342(8), 534–540 (2000).
   PubMed Web of Science ®Google Scholar
• Duff P, Lee ML, Hillier SL, Herd LM, Krohn MA, Eschenbach DA. Amoxicillin treatment of bacterial vaginosis during pregnancy. Obstet. Gynecol.77(3), 431–435 (1991).
   PubMed Web of Science ®Google Scholar
• Guaschino S, Ricci E, Franchi M et al. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur. J. Obstet. Gynecol. Reprod. Biol.110(2), 149–152 (2003).
   PubMed Web of Science ®Google Scholar
• Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N. Engl. J. Med.333(26), 1732–1736 (1995).
   PubMed Web of Science ®Google Scholar
• Joesoef MR, Hillier SL, Wiknjosastro G et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birthweight. Am. J. Obstet. Gynecol.173(5), 1527–1531 (1995).
   PubMed Web of Science ®Google Scholar
• Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet. Gynecol.97(5 Pt 1), 643–648 (2001).
   PubMed Web of Science ®Google Scholar
• Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ329(7462), 371 (2004).
   PubMed Web of Science ®Google Scholar
• Kurkinen-Räty M, Vuopala S, Koskela M et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG107(11), 1427–1432 (2000).
   PubMed Web of Science ®Google Scholar
• Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet. Gynecol.101(3), 516–522 (2003).
   PubMed Web of Science ®Google Scholar
• McDonald HM, O’Loughlin JA, Vigneswaran R et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br. J. Obstet. Gynaecol.104(12), 1391–1397 (1997).
   PubMedGoogle Scholar
• Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am. J. Obstet. Gynecol.171(2), 345–347; discussion 348–349 (1994).
   PubMed Web of Science ®Google Scholar
• Odendaal HJ, Popov I, Schoeman J, Smith M, Grove D. Preterm labour – is bacterial vaginosis involved? S. Afr. Med. J.92(3), 231–234 (2002).
   PubMed Web of Science ®Google Scholar
• Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet361(9362), 983–988 (2003).
   PubMed Web of Science ®Google Scholar
• Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br. J. Obstet. Gynaecol.106(7), 652–657 (1999).
   PubMedGoogle Scholar
• Jacobsson B, Pernevi P, Chidekel L, Jorgen Platz-Christensen J. Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. Acta. Obstet. Gynecol. Scand.81(11), 1006–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Genc MR, Vardhana S, Delaney ML, Witkin SS, Onderdonk AB. TNFA-308G>A polymorphism influences the TNF-α response to altered vaginal flora. Eur. J. Obstet. Gynecol. Reprod. Biol.134(2), 188–191 (2007).
   Google Scholar
• Macones GA, Parry S, Elkousy M, Clothier B, Ural SH, Strauss JF 3rd. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene–environment interaction in the etiology of spontaneous preterm birth. Am. J. Obstet. Gynecol.190(6), 1504–1508; discussion 1503A (2004).
   PubMed Web of Science ®Google Scholar
• Gomez LM, Sammel MD, Appleby DH et al. Evidence of a gene–environment interaction that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and DNA variants in genes that control the inflammatory response. Am. J. Obstet. Gynecol.202(4), 386.e1–6 (2010).
   PubMed Web of Science ®Google Scholar